30.30
Schlusskurs vom Vortag:
$31.01
Offen:
$30.96
24-Stunden-Volumen:
969.93K
Relative Volume:
0.81
Marktkapitalisierung:
$2.33B
Einnahmen:
$13.17M
Nettoeinkommen (Verlust:
$-199.06M
KGV:
-11.06
EPS:
-2.74
Netto-Cashflow:
$-156.53M
1W Leistung:
-4.08%
1M Leistung:
-4.60%
6M Leistung:
-24.16%
1J Leistung:
-30.90%
Xenon Pharmaceuticals Inc Stock (XENE) Company Profile
Firmenname
Xenon Pharmaceuticals Inc
Sektor
Branche
Telefon
(604) 484-3300
Adresse
200 - 3650 GILMORE WAY, BURNABY
Vergleichen Sie XENE mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
![]()
XENE
Xenon Pharmaceuticals Inc
|
30.30 | 2.38B | 13.17M | -199.06M | -156.53M | -2.74 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
469.65 | 121.28B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
563.10 | 60.96B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
328.81 | 42.77B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
591.99 | 36.21B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
291.47 | 32.08B | 3.81B | -644.79M | -669.77M | -6.24 |
Xenon Pharmaceuticals Inc Stock (XENE) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2025-05-07 | Eingeleitet | Chardan Capital Markets | Buy |
2025-02-11 | Eingeleitet | Deutsche Bank | Buy |
2024-10-10 | Fortgesetzt | Raymond James | Outperform |
2024-10-01 | Eingeleitet | H.C. Wainwright | Buy |
2024-01-04 | Eingeleitet | Citigroup | Buy |
2023-12-08 | Eingeleitet | Robert W. Baird | Outperform |
2023-10-24 | Fortgesetzt | Cantor Fitzgerald | Overweight |
2023-04-25 | Eingeleitet | Cantor Fitzgerald | Overweight |
2022-12-14 | Eingeleitet | Goldman | Buy |
2022-12-12 | Eingeleitet | Cowen | Outperform |
2022-11-28 | Eingeleitet | Wells Fargo | Overweight |
2022-10-19 | Eingeleitet | Raymond James | Outperform |
2022-08-29 | Eingeleitet | BofA Securities | Buy |
2022-07-21 | Eingeleitet | JP Morgan | Overweight |
2021-10-28 | Eingeleitet | RBC Capital Mkts | Outperform |
2020-10-02 | Eingeleitet | SVB Leerink | Outperform |
2020-07-21 | Eingeleitet | Needham | Buy |
2020-06-01 | Fortgesetzt | Jefferies | Buy |
2020-03-25 | Eingeleitet | Wedbush | Outperform |
2020-01-08 | Eingeleitet | William Blair | Outperform |
2019-09-20 | Eingeleitet | Guggenheim | Buy |
2018-08-08 | Bestätigt | Stifel | Buy |
2017-03-13 | Eingeleitet | Jefferies | Buy |
2016-10-21 | Eingeleitet | Stifel | Buy |
2016-09-26 | Eingeleitet | Guggenheim | Buy |
2016-04-14 | Bestätigt | Jefferies | Buy |
2015-10-30 | Fortgesetzt | Jefferies | Buy |
2014-12-02 | Eingeleitet | Canaccord Genuity | Buy |
Alle ansehen
Xenon Pharmaceuticals Inc Aktie (XENE) Neueste Nachrichten
What drives Xenon Pharmaceuticals Inc. stock priceMassive wealth growth - PrintWeekIndia
Xenon Pharmaceuticals Inc. Stock Analysis and ForecastExceptional ROI - PrintWeekIndia
What analysts say about Xenon Pharmaceuticals Inc. stockExplosive trading opportunities - Autocar Professional
Investors Buy Large Volume of Put Options on Xenon Pharmaceuticals (NASDAQ:XENE) - Defense World
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Shares Bought by Bank of New York Mellon Corp - Defense World
How Xenon Pharmaceuticals Inc. stock performs during market volatilityFree Access to Community - Newser
Is Xenon Pharmaceuticals Inc. a good long term investmentFree Stock Selection - jammulinksnews.com
Mutual of America Capital Management LLC Buys New Position in Xenon Pharmaceuticals Inc. (NASDAQ:XENE) - Defense World
Should I buy Xenon Pharmaceuticals Inc. stock before earningsFree Smart Money Stock Analysis - Newser
(XENE) Investment Analysis and Advice - news.stocktradersdaily.com
Teacher Retirement System of Texas Reduces Stake in Xenon Pharmaceuticals Inc. (NASDAQ:XENE) - Defense World
Why Xenon Pharmaceuticals Inc. stock attracts strong analyst attentionReliable High Profit Alerts - Newser
What makes Xenon Pharmaceuticals Inc. stock price move sharplyHigh Yield Opportunities - Newser
We're Hopeful That Xenon Pharmaceuticals (NASDAQ:XENE) Will Use Its Cash Wisely - Yahoo Finance
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Given Average Recommendation of “Buy” by Brokerages - Defense World
Traders Buy Large Volume of Put Options on Xenon Pharmaceuticals (NASDAQ:XENE) - Defense World
How to Take Advantage of moves in (XENE) - news.stocktradersdaily.com
CFO changes at Biocryst, Xenon, Century, Pyxis - biocentury.com
RBC Raises Xenon Price Target, Cites Phase III Optimism for Epilepsy Drug - MSN
Xenon Appoints CEO Ian Mortimer as Interim CFO - The Globe and Mail
XENE CEO Named Interim CFO After Sherry Aulin Resigns | XENE SEC FilingForm 8-K - Stock Titan
Xenon Pharmaceuticals Inc.(NasdaqGM:XENE) added to Russell Small Cap Comp Growth Index - MarketScreener
Xenon Pharmaceuticals: Riding the Russell Wave to Institutional Inflows and Clinical Milestones? - AInvest
Xenon Joins the Russell 3000® and Russell 2000® Indexes - The Manila Times
Xenon Pharmaceuticals added to Russell 3000 and 2000 indexes - Investing.com India
Xenon Pharmaceuticals Inc. Added to Russell 3000® and Russell 2000® Indexes in Annual Reconstitution - Quiver Quantitative
Xenon Pharmaceuticals added to Russell 3000 and 2000 indexes By Investing.com - Investing.com UK
Xenon Pharmaceuticals Announces Equity Inducement Grants to New Employees - TipRanks
Is Xenon Pharmaceuticals, Inc. overvalued or undervalued? - MarketsMojo
XENE: Xenon Pharmaceuticals Welcomes New Chief Commercial Officer | XENE Stock News - GuruFocus
Long Term Trading Analysis for (XENE) - news.stocktradersdaily.com
Xenon Pharmaceuticals Target of Unusually Large Options Trading (NASDAQ:XENE) - MarketBeat
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Receives Average Recommendation of “Buy” from Analysts - Defense World
RBC Capital Maintains Xenon Pharmaceuticals(XENE.US) With Buy Rating, Raises Target Price to $57 - 富途牛牛
Xenon Pharmaceuticals price target raised to $57 from $55 at RBC Capital - Investing.com Canada
Finanzdaten der Xenon Pharmaceuticals Inc-Aktie (XENE)
Umsatz
Nettogewinn
Free Cashflow
ENV
Xenon Pharmaceuticals Inc-Aktie (XENE) Insiderhandel
Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
---|---|---|---|---|---|---|---|
GANNON STEVEN | Director |
May 14 '25 |
Option Exercise |
12.57 |
5,144 |
64,660 |
7,144 |
MORTIMER IAN | PRESIDENT & CEO |
Jan 24 '25 |
Option Exercise |
17.76 |
22,468 |
399,032 |
53,770 |
MORTIMER IAN | PRESIDENT & CEO |
Jan 27 '25 |
Option Exercise |
17.76 |
16,315 |
289,754 |
46,468 |
MORTIMER IAN | PRESIDENT & CEO |
Jan 23 '25 |
Option Exercise |
17.76 |
16,217 |
288,014 |
47,519 |
MORTIMER IAN | PRESIDENT & CEO |
Jan 24 '25 |
Sale |
40.20 |
22,468 |
903,214 |
31,302 |
MORTIMER IAN | PRESIDENT & CEO |
Jan 27 '25 |
Sale |
40.50 |
16,315 |
660,806 |
31,302 |
MORTIMER IAN | PRESIDENT & CEO |
Jan 23 '25 |
Sale |
40.08 |
16,217 |
649,977 |
31,302 |
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):